Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan

BACKGROUND: Dexamethasone, remdesivir, and baricitinib reduce mortality in patients with coronavirus disease 2019 (COVID-19). A single-arm study using combination therapy with all three drugs reported low mortality in patients with severe COVID-19. In this clinical setting, whether dexamethasone adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirasawa, Yasutaka, Terada, Jiro, Shionoya, Yu, Fujikawa, Atsushi, Isaka, Yuri, Takeshita, Yuichiro, Kinouchi, Toru, Koshikawa, Ken, Tajima, Hiroshi, Kinoshita, Taku, Tada, Yuji, Tatsumi, Koichiro, Tsushima, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Respiratory Society. Published by Elsevier B.V. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110979/
https://www.ncbi.nlm.nih.gov/pubmed/37119744
http://dx.doi.org/10.1016/j.resinv.2023.03.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110979/
https://www.ncbi.nlm.nih.gov/pubmed/37119744
http://dx.doi.org/10.1016/j.resinv.2023.03.009

Ejemplares similares